Trial Profile
EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Sponsors Menarini
- 13 Jun 2019 This trial has been discontinued (prematurely ended) in UK, according to European Clinical Trials Database
- 02 Apr 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 23 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by United Kingdom Clinical Research Network record.